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Abstract  
 
The neurotoxins isolated from cone shell venoms are a diverse group of small, disulfiderich 
peptides. Most of the active peptides isolated to date have been shown to specifically target 
various components of neural transmission, and have generally demonstrated high specificities 
for ion channel and receptor types and subtypes. The specificity of conotoxins is one of the 
attributes that make them valuable diagnostic tools in the characterisation of neural pathways, as 
therapeutic agents in medicine, and potentially as biodegradable toxic agents in agroveterinary 
applications. The number of novel, active peptides within the numerous Conus species is 
considered to be enormous. Currently, however, relatively few peptides have been characterised. 
In this article, we review current research on conotoxins with a focus on drug potential being 
developed at the University of Queensland, Australia. 
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Introduction 
 
Ion channels as drug targets 
 
Voltage-dependent ion channels are intrinsic membrane proteins that play an important role in fast communication 
in excitable cells. A short stretch of amino acids, the pore region, is the sole determinant of cation selectivity and 
also forms the binding site for many channel blockers. Toxins that interact intimately with this region can be used as 
structural templates to deduce the spatial organisation of the pore region of the ion channels. These models of pore 
structure are valuable for understanding the mechanisms of ion permeation, and ultimately may be useful for the 
rational design of drugs that modify the function of ion channels in clinical conditions such as stroke, pain, or 
epilepsy. 
Broadly, ion channels have structural and functional similarities, but even within a class of ion channels 
there are significant differences that can be targeted in drug applications. The diversity and distribution of ion 
channel types and subtypes being uncovered through the use of molecular biology and toxin probes present an 
exciting opportunity for the discovery of new therapeutics which are specific for channel subtypes involved in 
disease states. The various ion channels to be considered will be examined briefly in turn. 
 
Nicotinic Acetylcholine Receptor-Channels 
 
The nicotinic acetylcholine receptor (nAChR) is part of the ligand-gated ion channel superfamily, which includes 
the GABAA, serotonin, and glutamate (NMDA, AMPA, kainate) receptors. All ligand-gated ion channels are large, 
membrane-bound pentamers with various subunit compositions. These receptors have several conserved features. 
Ligand-gated ion channels are pentamers, with each subunit containing four transmembrane helices (M1 to M4), 
with the M2 helix lining the ion channel lumen and providing it selectivity. Binding of an endogenous ligand to a 
large, extracellular domain remote to the M2 helix brings about a conformational change in the M2 helices that 
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causes the pore to open. Due to the size of these receptors (~290 kDa), the only direct structure determinations have 
been of low resolution (~9 Å) using electron microscopy [Unwin, 1998]. 
Nicotinic ACh receptors are found throughout the central and peripheral nervous systems, with distinct 
genes encoding the nAChR subunits which form a heteropentameric ion channel complex selective for cations. The 
muscle-subtype nAChR has been well characterised due to the availability of specific probes (e.g., a-bungarotoxin) 
and has the subunit composition (a1)2b1dg or e in mature muscle. In mammalian central and autonomic neurones 
and adrenal medulla, the neuronal nAChRs are composed of a and b subunits only. At least seven different a 
subunits (a2–a7 and a9) and three b subunits (b2–b4) have been identified and it has been shown that a2, a3, and a4 
can combine with b2 or b4 to form functional channels in the Xenopus oocyte expression system [McGehee and 
Role, 1995]. In addition, a7 and a9 subunits can be expressed as functional homooligomers in this system, with the 
a7 gene product being a-bungarotoxin-sensitive and highly permeable to Ca2+ [Colquhoun and Patrick, 1997]. 
Although these neuronal nAChR subunits are homologous with one another, each functional subunit combination is 
physiologically and pharmacologically distinct. This may account for the diversity of neuronal nAChRs observed in 
vivo. For example, the a5 subunit appears to participate in nAChRs expressed in heterologous systems and primary 
neurones and contributes to the pore lining of functionally unique nAChRs. Recent studies using single cell RT-PCR 
analysis of nAChR gene transcripts indicate that multiple nAChR subtypes are expressed by individual rat 
intracardiac neurones and that the combination of subtypes expressed varies among cells [Poth et al., 1997]. The 
development of specific pharmacological probes for neuronal nAChR subunits will provide new insight into the 
structural composition and functional role of the different neuronal nAChRs subtypes. 
Activation of distinct subtypes of these presynaptic nAChRs by nicotinic agonists can selectively regulate 
the release of different neurotransmitters, including dopamine, norepinephrine, glutamate, and acetylcholine [Kulak 
et al., 1997; Kaiser et al., 1998; Picciotto et al., 1998]. Such receptors have also been implicated in the 
pathophysiology of several neuropsychiatric disorders, including schizophrenia, Alzheimer’s disease, Parkinson’s 
disease, and Tourette’s syndrome [Kulak et al., 1997]. Despite their importance, few of the nicotinic receptor 
antagonists identified to date are highly selective between the multiple neuronal nAChR subtypes. Thus, the ability 
of recently discovered a-conotoxins — small (12–19 amino acids), rigid, highly disulfide-bonded peptides isolated 
from marine snails of the genus Conus — to target neuronal nAChR subunits with high specificity has considerable 
significance for both basic neuroscience and potential drug development. 
 
Sodium Channels 
 
Sodium channels consist of three separate and biochemically separable protein subunits, the a plus b-1 and b-2 
auxiliary subunits, which comprise the channel in a 1:1:1 stoichiometry. The a-subunit is a transmembrane 
glycoprotein of approximately 260 kDa molecular weight that binds a diverse range of neurotoxins at specific 
positions on its surface (six or seven sites are currently identified). The two b-subunits have smaller molecular 
weights (~30 kDa each) and are integral membrane glycoproteins. Numerous models of sodium channel a-subunit 
structure have appeared, based on primary sequence data [Noda et al., 1984]. All show four highly homologous 
regions of sequence domains, labeled I–IV, with each domain containing six transmembrane helices, denoted S1–
S6. The S5 and S6 segments of each domain are highly nonpolar, the S1, S2, and S3 segments are relatively 
nonpolar, with just a few charged sidechains, but the S4 segments within each domain have the distinctive feature 
that every third residue is positively charged (mostly arginines). The S4 segments are believed to move upward on 
depolarisation to open the activation gate (m gate) and allow the selective influx of sodium ions. In the process, 
voltage-dependent movement of an IFM particle to interact with adjacent intracellular loops is facilitated and 
inactivation occurs, blocking the further flow of ions (Fig. 1). 
There is considerable structural homology among the three types of brain Na+ channel a-subunits (I, II, and 
III), the m1-sodium channel a-subunit from adult skeletal muscle, and the h1 sodium channel a-subunit from heart 
and denervated muscle. Despite these similarities, considerable pharmacological diversity exists. For example, 
tetrodotoxin (TTX) blocks the brain types I, II, and III at nanomolar concentrations, and the h1 form from the heart 
at micromolar concentrations. 
Until recently, there was no hard evidence to indicate that pharmacologically distinct forms of neuronal 
sodium channels are expressed in sensory neurons, and thus no evidence that a specific Na+ channel pathway could 
be modulated to control particular diseases. The newly discovered TTX-insensitive sodium channel, named PN3 or 
SNS [Sangameswaran et al., 1996], which is located specifically in sensory neurons, represents one of a number of 
potential Na+ channel targets for drug discovery. Additional neuronal pathways for therapeutic intervention may 
also be uncovered using conopeptides such as m-conotoxin PIIIA, the first conopeptide to distinguish amongst 
neuronal TTX-sensitive Na+ channels [Shon et al., 1998; Watson et al., 1998]. 
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Calcium Channels 
 
Structurally, the calcium channels are closely related to sodium channels, with the main difference being the 
positioning and nature of the residues that line the selectivity filter in the pore of the channel. There are at least six 
pharmacologically distinct calcium channels types, including L-, N-, P/Q-, T, and R-type calcium channels, and 
within each group are multiple subtypes that are presently less easy to distinguish. In the nervous system, several 
types of ion channels may contribute to processes such as neurotransmitter release, with the ratio and role for each 
type varying among different nervous tissues [Olivera et al., 1994]. This situation provides the possibility for 
selective modulation of nerve function with type and subtype selective modulators that may allow the selective 
treatment of conditions such as pain and stroke. The w-conotoxins have been of enormous importance as 
physiological tools, with currently one peptide (MVIIA or Ziconitide) in clinical trials for pain and stroke. 
 
Potassium Channels 
 
There are numerous types of potassium channel, each with its own distinctive electrophysiological and 
pharmacological properties; what they all have in common is that they tend to stabilise the membrane potential at 
the K+ equilibrium potential. DNA sequencing reveals that the potassium channels encoded by Drosophila and 
vertebrate genes all resemble a single domain of the voltage-dependent sodium channel [Jan and Jan, 1997]. 
Voltage-dependent potassium channels are tetrameric homo-oligomers organised in axial fourfold symmetry around 
the K+-selective pore. Analogous to voltage-dependent sodium and calcium channels, the S4 transmembrane 
segment carries a cluster of positively charged residues and is thought to act as the voltage sen- sor for channel 
activation. Site-directed mutagenesis studies, coupled with the use of selective toxins, have proved invaluable in 
unraveling which residues of the potassium channel protein are functionally important. Recently, the crystal 
structure of a K+ channel has been determined [Doyle et al., 1998]. The pore structure determined previously from 
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toxin binding interaction studies has proved to be remarkably predictive [Miller, 1995], though it lacks the structural 
detail obtained by X-ray crystallography. k-Conotoxin PVIIA is a new structural class of K+ channel blocking 
peptide that binds in a voltage- sensitive manner to the outer vestibule of the channel [Scanlon et al., 1997]. 
 
Discovery and Characterisation of Novel Conotoxins 
 
Tropical waters, especially in coral reef ecosystems, house an extraordinary diversity of invertebrate 
species, many of whom use novel bioactive compounds as part of defensive or prey capture strategies. The cone 
shells which comprise a group of some 500+ predatory molluscs are the most specialised, with venoms that target 
fish, worms, and other molluscs. The venom is injected through a harpoon-like apparatus and contains a complex 
mix of small, constrained peptides which contain 10–40 amino acids and up to five disulfide bonds [Myers et al., 
1993]. This cocktail of peptides targets a diverse range of voltage-sensitive sodium, calcium, and potassium 
channels and N-methyl-d-aspartate, glutamate, vasopressin, serotonin, and acetylcholine receptors, which leads to an 
immediate and efficient immobilisation of the prey. The conotoxins present in the venom have been divided into a 
number of major classes based on their pharmacological activity and cysteine frameworks (Table 1). Their high 
potency and specificity, and convenient chemical synthesis, also make the conotoxins attractive leads in drug design 
programs. In addition to the conotoxins being among the smallest bioactive peptides, they are unusual in containing 
a high density of cysteine residues and posttranslation modifications, including hydroxylation, carboxylation, 
amidation, sulphation, and bromination. These features often complicate their chemical characterisation and 
occasionally their chemical synthesis. All major classes of conotoxins have been identified through initial in vitro or 
in vivo functional assays [Olivera et al., 1990]. Screening based on receptor-binding displacement of radiolabeled 
ligands is also playing a major role. At the 3D Centre, University of Queensland, sensitive 125I-GVIA and 125I-
MVIIC assays have been established for rat and human brain preparations to allow for the isolation of new w-
conotoxins. More recently, other chemical and molecular biology approaches have facilitated the identification and 
primary structure determination of new conotoxins. In practice, all of these approaches are used in concert to 
discover new conotoxins. 
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The realisation that most if not all conotoxins were biologically active led us to establish chemical 
approaches to rapidly identify new conotoxins and confirm the presence of known conotoxins. The starting source of 
venom was either from the dissected venom ducts of Conidae or from the milked venom of captive species. The 
venom paste was then extracted with varying amounts of acetonitrile acidified with 0.1% trifluoroacetic acid. This 
procedure efficiently extracts most of the conotoxins present. Early research findings at the 3D Centre revealed 
considerable inter- and intraspecies variability in the components in cone shell venoms and also that most species 
contained in excess of 100 different peptides [Bingham et al., 1996]. This analysis was facilitated by the application 
of Ionspray mass spectrometry, which dramatically reduced the time and quantity of venom required to characterise 
the components of these complex mixtures [Lewis et al., 1994; Bingham et al., 1996; Jones et al., 1996]. An 
example of an LC/MS analysis of the peptides present in the crude venom from Conus geographus is given in 
Figure 2. From analyses of more than 30 species, it is evident that the 60+ conotoxins reported to date represent less 
than 0.1% of the peptides present in the venoms of Conidae. 
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HPLC/electrospray mass spectrometry analysis is generally complemented with a suite of chemical 
techniques to rapidly “mass profile” each crude venom. The tagging of each molecular component has facilitated the 
subsequent isolation and characterisation of novel peptides. Fractionation of the venom is often directed by the mass 
and number of disulfide bonds present in the peptide. Posttranslational modifications, which are common in cone 
shell venoms, are usually identified by MS/MS, enzymatic degradation/MS studies, amino acid analysis, and Edman 
chemistry [Loughnan et al., 1998]. Fortunately, most conopeptides are not N-terminally blocked. 
The determination of disulfide bond connectivity for many conotoxins remains challenging. Classical 
approaches using enzymic degradation often fail, as most conotoxins are resistant to proteolysis, even with high 
levels of enzyme present. Success has been achieved using a reductive alkylation/Edman sequence strategy [Gray, 
1993]. However, this approach occasionally fails, as the alkylation step is performed under basic conditions where 
scrambling may occur. Recently, we developed a more general approach that employs both mass spectrometry and 
Edman chemistry [Jones et al., 1996]. Briefly, the conotoxin is sequentially reduced and alkylated under acidic 
conditions with mass spectrometric/ HPLC analysis and Edman sequencing. For smaller peptides (e.g., the a-
conotoxins), the differentially alkylated products need only be subjected to collision-induced dis sociation to locate 
the labeled cysteine residues and hence deduce the disulfide bond connectivity pattern. 
Conotoxins are synthesised by cone shells from mRNA templates derived from toxin genes, and expressed 
in the venom ducts as precursor peptides. There are now numerous gene cloning techniques that can be used to 
isolate and characterise the precursor molecules, as a prelude to predicting the composition of the mature peptide. 
The mRNA can be isolated and converted to either single-stranded (ss) or double-stranded (ds) complementary 
DNA (cDNA). Cloning of the ds-cDNA produces a venom duct library, which can be screened with DNA probes 
from known toxin mature peptide sequence or precursor peptide sequence to find closely related clones. This 
strategy was successfully used to isolate and define the precursor structure of the w-conotoxin GVIA from a C. 
geographus library [Colledge et al., 1992]. An alternative approach is to make use of polymerase chain reaction 
(PCR) technologies. In this method, oligonucleotide primers homologous to known mature peptide sequence can be 
used to derive 5¢ leader propeptide and untranslated sequence using adaptor ligated ds-cDNA (5¢RACE). This 
sequence can then be used to identify conserved regions in the precursor leader sequences in which to position 
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oligonucleotide primers that are specific to conopeptide families. PCR using these specific primers in conjunction 
with a 3¢ anchor primer on venom duct ss-cDNA will produce amplified copies of the expressed peptides in that 
particular family (3¢ RACE). Cloning and sequencing will produce the full peptide sequence, from which the 
mature peptide region can be predicted. Apart from the targeted approaches of the library and PCR strategies, the 
complete screening of venom duct cDNA libraries in a manner similar to an EST (expressed sequence tag) strategy 
is quite feasible and very productive. Most conopeptide sequences are less than 1,000 nucleotides, allowing 
complete sequencing of each peptide gene simply by using primer sites based on the vector sequence of the clones. 
While the molecular cloning methods of conotoxin isolation does have a number of distinct benefits in comparison 
to assay directed fractionation of whole venom, they have the disadvantage of not being able to predict 
posttranslational modifications of the mature peptides. Conopeptides can be highly and unusually modified, such as 
the alpha peptide EpI, which has a sulphated tyrosine [Loughnan et al., 1998]. These modifications provide chemical 
alterations that may well be important in the activity of the conopeptide at the receptor target. At present, the gene 
structures that combine to produce a toxin peptide precursor mRNA transcript are not known. The identification of 
these genes and the mRNA splicing pathways that ultimately produce the highly variable toxin peptides will provide 
a much better understanding of toxin peptide evolution in the Conus species, and will undoubtedly lead to more 
effective strategies for library-based and PCR-based toxin peptide isolation. 
 
Conotoxin Synthesis, folding, and purification 
 
All conotoxins described to date, with the exception of the conantokins, contain multiple disulfide bonds. Unlike 
studies on other animal toxins (e.g., snakes, scorpions), both the complexity of the venom and the small quantities 
available (usually micrograms) preclude indepth studies on the native material. Solid phase peptide synthesis has 
been the most successful approach in providing significant quantities of these peptides for biological and structural 
studies. Most often this has been achieved through synthesis of the fully reduced polypeptide before “folding” under 
oxidative conditions. Although this approach yields the desired peptide, in many instances it is present in a mixture 
of other “wrongly” or partially folded isomers. The nonnative isomers differ solely in the connectivity of their 
disulfide bridges and can be difficult to separate from the native material, leading to reduced yields of pure 
conopeptide. 
 
Directed Folding 
 
Conotoxin GI is part of the a-conotoxin family and contains 13 residues with two intramolecular disulfide bridges. 
Various oxidative techniques on fully reduced a-conotoxin GI yield mixtures of all three potential isomers with the 
native isomer a-CTX GI(2-7;3-13) generally predominating. We recently described an on-resin “directed-disulfide” 
strategy to gain access to each isomer [Alewood, 1998]. This is illustrated in the directed synthesis of the native 
isomer (Fig. 3). The orthogonal protecting groups acetomidomethyl (Acm) and fluorenylmethyl (Fm) were chosen 
to allow stepwise regiospecific disulfide formation on the resin. Chain assembly was performed using standard Boc 
chemistry [Schnölzer et al., 1992] on p-methylbenzhydrylamine resin. The Fm group was removed and oxidised 
with piperidine-DMF. Deprotection and oxidation of the Acm group by iodine in DMF led to the formation of the 
second disulfide bond. Final HF cleavage led to deprotected “crude” conotoxin containing minor amounts of 
polymer. Reversed-phase HPLC analysis confirmed that only the native isomer was formed. The two nonnative 
isomers of a-conotoxin GI were made employing a similar strategy. 
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Rapid Solid Phase Peptide Synthesis (SPPS) 
 
A bottleneck in structure–function studies of the conotoxins has been the availability of the desired mutants within a 
reasonable time frame. The small number of such studies reflects, in part, the difficulties in the synthesis and folding 
of these cysteine-rich frameworks. As such there is a pressing need to develop faster, more efficient chemistry. 
In recent years, there have been efforts [Schnölzer et al., 1992; Alewood et al., 1997] by several groups to 
improve the speed and efficiency of SPPS. The introduction of HBTU/in situ neutralisation chemistry has allowed 
routine synthesis where three residues per hour are incorporated in the growing peptide chain. The further 
development of improved acylating agents such as HATU has opened up the possibility of more rapid synthetic 
procedures using HATU/Boc in situ neutralization [Alewood et al., 1997]. This is illustrated by the rapid chain 
assembly of the A10L mutant of PnIA conotoxin from Conus pennaceus, which blocks the nicotinic acetylcholine 
receptor. The conotoxin was assembled in a little over 1 h, worked up, and oxidised to give fully folded 
homogeneous material within a day. 
 
Conotoxin Folding 
 
Most reduced forms of native conotoxins are capable of folding efficiently. The folding/oxidation thus remains a 
matter of probing sufficient “folding” space so that the desired conotoxin forms uniquely or as the predominant 
product. Whereas many laboratories have the capacity to isolate quantities of the reduced purified precursors, their 
efforts at the “folding” stage have often been inadequate. This may be a direct result of not having access to native 
material for comparison. This is particularly important in cases where the disulfide bond connectivity of the 
conotoxin has not been unambiguously determined. 
More specifically, the folding of w-conotoxins has caused difficulties in several laboratories where 
nonnative isomers have formed a significant proportion of the oxidised products. This is readily illustrated in the 
folding of the N-type neuronal calcium channel blocker, GVIA (Fig. 4), where the selection of inappropriate though 
commonly used folding conditions (trace E) led exclusively to nonnative products. Moreover, the selection of 
“appropriate” folding conditions (trace A) yielded almost exclusively the correctly folded native conotoxin. 
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Structure determination of conotoxins by NMR 
 
NMR spectroscopy is now a well-established method for structure determination of peptides and pro teins. The 
method relies on the measurement of a large number of distance restraints between pairs of protons. These restraints 
are used in a simulated annealing protocol to calculate a family of structures consistent with both the input restraints 
and with a force-field defining covalent geometry of atoms. Distance restraints are often supplemented with 
restraints on peptide backbone and sidechain dihedral angles. The distance restraints are derived from NOESY 
spectra and the dihedral restraints from a combination of coupling constant and NOE data. Depending on the size of 
the protein being studied and the complexity of the spectra, 2D, 3D, or 4D NMR methods may be required. The 
higher dimensional spectra (i.e., 3D or 4D) generally require uniform labeling of the protein with 15N and/or 13C 
isotopes so that spectral overlap may be resolved using the additional frequency dimensions associated with these 
NMR active nuclei, as well as the usual proton chemical shift axis. 
An assumption inherent in the NMR structure determination method is that the peptide or protein adopts 
predominantly a single conformation in solution. For linear peptides comprising fewer than approximately 30 amino 
acid residues this is often not the case, with such small peptides being extremely flexible and adopting a myriad of 
conformations in solution. Thus, for these peptides only qualitative conclusions can be drawn about solution 
conformations. However, peptides which are cross-linked by disulfide bonds are more restrained in their 
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conformations and are very suitable for quantitative structure determination by NMR. As indicated above, the 
conotoxins are rich in disulfide bonds and are hence particularly amenable to conformational analysis by NMR. 
An additional advantage of conotoxins is that their small size (generally less than 30 residues) means that 
spectral overlap is generally not a problem, and 2D rather than 3D or 4D NMR methods are sufficient for spectral 
assignment and structure determination. Because isotopic labeling is not required for such studies, it is in principle 
possible to determine structure from native peptides extracted from venom ducts. However, in practice the amounts 
of material required (~1 mg) generally means that it is more convenient to synthesise the conotoxins using the 
methods described above. 
Over the last few years we have determined the structures of more than 30 conotoxins (from all the known 
classes and from novel ones as yet unreported) and are using these structures in several drug design programs. From 
these studies, and from studies by colleagues in the literature, it has become clear that conotoxin structures fall into a 
limited number of families. Representatives of these structural families are summarised in Figure 5. 
From these structures it can be seen that the a- conotoxins adopt a fold such that the N- and C-termini are 
brought into close proximity by the internal disulfide bonds, and that a short helical segment is present. By contrast, 
the structures of the m-, k-, and w-conotoxins are dominated by a series of loops which are superimposed on a core 
comprising well-defined elements of secondary structure. For the m-conotoxins these secondary structure elements 
include a helical region and a b-hairpin, while the k- and w-conotoxins contain a triplestranded b-sheet. The 
conantokins have no disulfide bonds, but adopt helical structures [Skjaerbaek et al., 1997]. We return later to a more 
extensive discussion of specific details of some of these structures, but emphasise here that the conotoxins clearly 
may be regarded as “mini-proteins” and adopt well-defined solution structures with all of the features of larger 
proteins. The defined presentation of amino acids on the surface of the frameworks in Figure 5 accounts for the 
specificity of their binding interactions and the small size of the molecules makes them valuable lead compounds in 
drug design applications. 
 
Drug Development Research (1999) 46 (3-4), 219-234.   doi: 10.1002/(SICI)1098-2299(199903/04)46:3/4<219::AID-
DDR7>3.0.CO;2-S 
 
 
 
Conotoxins Which Block the Nicotinic ACh Receptor 
 
There are several classes of ligands that bind to the nAChR. These comprise small molecules, such as the 
endogenous ligand agonist acetylcholine, small peptides, including the lophotoxins and a-conotoxins, and large 
peptide toxins isolated from snake venoms (e.g., a- bungarotoxin). The a-conotoxins are widespread in the venoms 
of cone snails and have been isolated from piscivorous, molluscivorous, and vermivorous species [Gray et al., 1981; 
McIntosh et al., 1982, 1994; Zafaralla et al., 1988; Myers et al., 1991; Ramilo et al., 1992; Fainzilber et al., 1994; 
Martinez et al., 1995; Loughnan et al., 1998]. These toxins are valuable ligands for probing structure– function 
relationships of various nAChR subtypes as they are potent antagonists and exhibit marked selectivity between the 
peripheral and neuronal forms of the receptor. Typically, the a-conotoxins are 12–18 residues in length and are 
characterised by the presence of two conserved disulfide bonds and two loops in the peptide backbone between the 
cysteines. The number of amino acids in these two intra-cysteine loops varies, giving rise to the a3/5, a4/7, and a4/3 
subclasses of a-conotoxins. 
The affinity of a given a-conotoxin depends both on the species and the subtype of nAChR present. The 
first a-conotoxins discovered were found to bind to the muscle-type nAChR (e.g., a-conotoxin GI) through a highly 
selective interaction at the a–d over the a–g subunit interface [Hann et al., 1994; Groebe et al., 1995]. Recent studies 
have described the isolation and characterisation of a-conotoxins selective for neuronal nAChRs and the molecular 
basis of the interaction of these a-conotoxins with the nAChR is beginning to be revealed. For example, a-conotoxin 
ImI selectively targets the homomeric a7 and a9 subtypes of neuronal nAChR [Johnson et al., 1995], whereas a-
conotoxin MII was found to potently block a3b2 nAChRs expressed in Xenopus oocytes with an IC50 of 0.5 nM 
[Cartier et al., 1996; Harvey et al., 1997]. The structure of MII differs significantly from the other a-conotoxins; 
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however, the disulfide bonding is conserved and it has the a 4/7 spacing like a-conotoxins PnIA, PnIB, and EpI. a-
Conotoxins 
PnIA and PnIB from C. pennaceus have been reported to have a different phylogenic specificity compared 
to the other a-conotoxins, in that they block neuronal nAChRs in molluscs [Fainzilber et al., 1994]. However, in 
preliminary experiments on dissociated rat parasympathetic neurones, we found that a-conotoxins PnIA[A10L] and 
PnIB (0.1–1 mM) inhibit the a-bungarotoxin- sensitive component of the ACh-evoked current [Hogg et al., 1999], 
and identified EpI as a new selective neuronal nAChR antagonist [Loughnan et al., 1998]. We believe that the 
growing diversity of a- conotoxins in terms of their selectivity, not only between muscle and neuronal nAChR 
subtypes but between neuronal a subunits, will provide the molecular tools needed to probe and distinguish between 
neuronal nAChR subtypes so that their distinct function(s) can be understood. 
As a result of recent studies in our laboratories, Xray crystal structures have been determined for GI 
[Guddat et al., 1996], PnIA [Hu et al., 1996], and PnIB [Hu et al., 1997], EpI [Hu et al., 1998], ImI and SII 
(unpublished structures). Combined with NMR solution structures of a similar range of a-conotoxins, they provide 
initial insights into the putative binding surface of these peptides. Comparison of the published structures of the a-
conotoxins indicates that their backbones are superimposable. This structural consensus allows us to model 
differences in specificity and potency for AChRs with differences in the position of exposed sidechains in the a-
conotoxins. From this analysis we will identify residues important for selectivity, allowing us to design new 
selective a-conotoxins. To illustrate recent work from our laboratory in this class of conotoxins, we describe studies 
on conotoxin GI, the first and one of the smallest a- conotoxins to be discovered, and on MII, a recently discovered 
member of the family with selectivity of neuronal nAChRs. The sequence and characteristics of these peptides are 
given in Table 2. 
 
 
 
Conotoxin GI 
 
Our interest in GI has focused on its use as a model to explore conformational diversity resulting from disulfide 
bond engineering. As already noted, conotoxins are characterised by their particularly high content of cysteine, with 
the cysteine residues almost invariably connected in pairs to form disulfide bonds. In peptide toxins, even more so 
than in larger proteins, these disulfide bonds have a crucial bearing on three-dimensional structure and function. As 
the number of cysteine residues in a peptide increases, the number of ways of connecting the cysteines in disulfide 
bonds increases dramatically, leading to a large number of potential isomers. It is interesting and highly significant 
that invariably only one of the possible isomers occurs naturally, i.e., venoms do not nor mally contain different 
isomers of the same conotoxins with different connections of the disulfide bonds. However, using solid phase 
chemical methods it is possible to selectively produce each of the individual disulfide bond isomers. As noted in a 
section above, we used this approach to synthesise all three possible disulfide bond isomers of the a-conotoxin GI 
and have determined their structures [Gehrmann et al., 1998]. We refer to the three isomers as GI(2-7;3-13), GI(2-
13;3-7), and GI(2-3;7-13). 
The structural findings may be summarised by noting that the native connectivity of the four constituent 
cysteine residues produces a significantly more stable and well defined structure than either of the two alternative 
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arrangements of the disulfide bonds [Gehrmann et al., 1998]. A single solution conformation was detected for the 
native isomer, GI(2-7;3-13), which consists primarily of a distorted 310 helix from residues 5 to 11. The two 
nonnative forms exhibit multiple conformations in solution, with the major populated forms being different in 
structure both from each other and with the native form. We concluded that the disulfide bonds in GI play a major 
role in determining both the structure and stability of the peptide. A trend for increased conformational flexibility 
was observed in the order GI(2-7;3-13) < GI(2- 13;3-7) < GI(2-3;7-13). 
Interest in making nonnative isomers arises because peptide analogues are widely regarded as valuable 
drug leads, and in recent years there has been much effort directed towards the development of peptide libraries. It 
has been of particular interest to develop methods to increase the surface variability of peptides because the diversity 
of peptide libraries are, to some extent, limited by the use of the 20 natural amino acids. The study described above 
shows that the use of alternative disulfide bond connectivities provides another way of altering molecular 
conformations without modifying the sequence. 
 
Conotoxin MII 
 
The recently identified a-conotoxin MII from C. magus belongs to the a4/7 subclass and is a potent and highly 
specific blocker of mammalian neuronal nAChRs composed of a3b2 subunits. MII was first reported by Cartier et al. 
[1996] following the electrophysiological screening of RP-HPLC fractions of duct venom against cloned nAChRs 
expressed in Xenopus oocytes. We independently isolated and characterised MII as part of a comprehensive study of 
the milked venom of C. magus and recently reported its three-dimensional structure [Hill et al., 1998]. 
The molecule folds into a highly compact globular structure consisting of a central region of a-helix and a 
series of overlapping b-turns at the N- and Ctermini. The a-helix comprising residues 6–12 exhibits two turns and is 
amphipathic, with Cys8, His9, Glu11, and His12 on one side and Pro6, Val7, and Leu10 on the other. Remarkably, 
the hydrophobic residues of the a-helix are more exposed to the solvent than the charged/hydrophilic residues. 
However, this is consistent with the fact that MII is more hydrophobic when oxidised than in the reduced form. 
Hydrophilic residues on the surface include Ser4, Asn5, and residues Glu11, His12, Ser13, and Asn14. The latter 
patch, comprising residues with both polar and charged groups (Glu11-Asn14), may be responsible for initial 
recognition by the nAChR, with further stabilisation of binding provided by the proximal hydrophobic residues. 
Analysis of the solvent accessibility of individual residues provides support for Pro6, Val7, Leu10, Glu11, and Asn 
14 as potential residues for interaction with the nAChR as they are highly solvent exposed [Hill et al., 1998]. 
 
Sodium Channel Binding Conotoxins 
 
The piscivorous cone snail, C. geographus, produces polypeptide neurotoxins that specifically inhibit skeletal 
muscle and eel electroplax sodium channels [Sato et al., 1983; Cruz et al., 1985; Yanagawa et al., 1988; 
Moczydlowski et al., 1986]. These toxins, the m-conotoxins and conotoxin GS, are attractive probes of sodium 
channel structure because of their high binding affinity and ability to discriminate between the skeletal muscle and 
neuronal and cardiac channel isoforms [Yanagawa et al., 1988; Moczydlowski et al., 1986; Ohizumi et al., 1986; 
Chen et al., 1992]. It is remarkable that while these peptides belong to the same pharmacological class they have 
different structural frameworks, as illustrated in Table 1. 
The m-conotoxins, a family of highly basic 22-residue polypeptides (GIIIA, GIIIB, and GIIIC), contain six 
cysteine residues which are paired in a 1–4, 2–5, 3–6 pattern to form three intramolecular disulfide bonds and a 
three-loop framework. Conotoxin GS has a strikingly different sequence and is 50% larger than the m- conotoxins. 
This polypeptide contains six cysteine residues arranged in a similar 1–4, 2–5, 3–6 pattern [Nakao et al., 1995]; 
however, differences in the spacings between cysteine residues results in a four-loop framework rather than a three-
loop framework. Despite the low sequence identity, conotoxin GS binds competitively with m- conotoxin GIIIA, 
suggesting overlapping binding sites on the extracellular surface of skeletal muscle and eel electroplax sodium 
channels [Yanagawa et al., 1988]. 
 
Conotoxin GIIIB 
 
GIIIB adopts a compact structure [Hill et al., 1996] consisting of a distorted 310-helix, a small b-hairpin, a 
cishydroxyproline, and several turns. The molecule is stabilised by three disulfide bonds, two of which connect the 
helix and the b-hairpin, forming a structural core with similarities to the CSab motif [Cornet et al., 1995]. This motif 
is common to several families of small proteins, including scorpion toxins and insect defensins. Other structural 
features of GIIIB include the presence of eight arginine and lysine sidechains that project into the solvent in a radial 
Drug Development Research (1999) 46 (3-4), 219-234.   doi: 10.1002/(SICI)1098-2299(199903/04)46:3/4<219::AID-
DDR7>3.0.CO;2-S 
orientation relative to the core of the molecule. These cationic sidechains form potential sites of interaction with 
anionic sites on sodium channels. The global fold is similar to that reported for m- conotoxin GIIIA, and together the 
structures provide a basis for further understanding of the structure–activity relationships of the m-conotoxins and 
for their binding to skeletal muscle sodium channels. 
 
Conotoxin GS 
 
The three-dimensional structure of conotoxin GS [Hill et al., 1997] consists of a compact, disulfide-bonded core 
from which several loops and the C-terminus project. The main element of secondary structure is a doublestranded 
antiparallel b-sheet comprising residues 17–20 and 26–29 connected by a turn involving residues 21–25 to give a b-
hairpin structure. A further peripheral b-strand involving residues 7–9 is almost perpendicular to the b- hairpin, with 
only Ser7 hydrogen-bonded to the central b-strand forming an isolated b-bridge. 
GS is unusual in that it contains the posttranslationally modified residue g–carboxy glutamic acid. To 
investigate the role of Gla32 in this polypeptide, an analog [Glu32]conotoxin GS was synthesised and the NMR 
spectra compared with those of conotoxin GS. The chemical shift differences for the backbone Ha and NH protons 
of conotoxin GS and [Glu32]conotoxin GS were small (£0.05 ppm), suggesting that the backbone conformation of 
the two peptides is essentially identical. Several other parameters, including the observed NOEs, 3JNH-Ha coupling 
constants and amide exchange rates are similar, providing further evidence of conserved structure in these peptides. 
This suggests that the Gla residue does not play a role in modulating the three-dimensional structure of conotoxin 
GS. 
As the sequence and structure of conotoxin GS is quite different from the m-conotoxins, it provides a 
valuable new probe for further characterisation of sodium channel geometry. The structure of conotoxin GS will 
facilitate the design of analogues to define the binding surface and to undertake complementary mutagenesis on the 
sodium channel to identify the interacting residues. These experiments with conotoxins may prove as useful in 
modeling the outer vestibule of sodium channels as the peptide toxins from scorpions have been for potassium 
channels. 
 
Calcium Channel Blocking Conotoxins 
 
The w-conotoxins are a set of structurally related peptides that have a wide range of specificities for different 
subtypes of the voltage-sensitive calcium channel (VSCC). To understand their VSCC subtype differentiation, we 
studied the structure of two naturally occurring w-conotoxins, MVIIA (specific to N-type VSCCs) and SVIB 
(specific to P/Q-type) and a synthetic hybrid, SNX- 202, which has altered specificities to both VSCC subtypes 
[Nielsen et al., 1996]. The secondary structures of the three peptides are almost identical, consisting of a triple-
stranded b-sheet and several turns. The three-dimensional structures of SVIB and MVIIA are likewise quite similar, 
but some subtle differences are manifested as orientational differences between two key loops. 
A remarkable feature of the six cysteine / four-loop framework exemplified by the w-conotoxins is the 
presence of a cystine knot within the structures. This motif consists of an embedded loop in the structure formed by 
two of the disulfide bonds and their connecting backbone segments. This loop is penetrated by the third disulfide 
bond in a remarkable example of Nature’s engineering designs. 
Although the structural rigidity of the core of MVIIA is apparently assured by the knotted disulfide 
structure, we used NMR to probe for possible conformational flexibility in the exposed loops. As indicated above, it 
is important be aware of potential conformational changes that might affect receptor binding. In the case of MVIIA, 
the Ha shifts were found to be similar in a range of solvents, indicating that there are no solventinduced changes in 
structure. 
From the above structural studies and a large number of other studies of molecules within this family it is 
apparent that the w-conotoxins form a consensus structure despite differences in sequence and VSCC subtype 
specificity. This indicates that the w-conotoxin macrosites for the N/P/Q-subfamily of VSCCs are related, with 
specificity for receptor targets being conferred by the positions of functional sidechains on the surface of the 
peptides. 
As mentioned earlier, the w-conotoxins have attracted the most interest for potential pharmaceutical 
applications. Indeed, conotoxin MVIIA is currently in clinical trial for the treatment of chronic pain. Structural 
studies of the type described above are likely to lead to the development of second-generation analogues which may 
overcome some of the side effects of MVIIA itself. 
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Potassium Blocking Conotoxins 
 
k-PVIIA is a 27-residue polypeptide isolated from the venom of C. purpurascens and is the first member of a new 
class of conotoxins that block potassium channels. By comparison to other ion channels of eukaryotic cell 
membranes, voltage-sensitive potassium channels are relatively simple and methodology has been developed for 
mapping their interactions with small peptide toxins. PVIIA, therefore, is a valuable new probe of potassium channel 
structure. In a recent study, we determined the solution structure and mode of channel binding of PVIIA [Scanlon et 
al., 1997] and this forms the basis for mapping the interacting residues at the conotoxin–ion channel interface. 
The three-dimensional structure of PVIIA resembles the triple-stranded b-sheet / cystine knot motif formed 
by a number of toxic and inhibitory peptides, including the w-conotoxins and conotoxin GS, as described above. 
Subtle structural differences, however, predominantly in loops 2 and 4, are observed between PVIIA and other 
conotoxins with similar structural frameworks. Electrophysiological binding data suggest that PVIIA blocks K+ 
channel currents by binding in a voltage-sensitive manner to the external vestibule and occluding the pore. 
Comparison of the electrostatic surface of PVIIA with that of the well-characterised potassium channel blocker 
charybdotoxin suggested a likely binding orientation for PVIIA. Although the structure of PVIIA is considerably 
different from that of the aK scorpion toxins, it has a similar mechanism of channel blockade. On the basis of a 
comparison of the structures of PVIIA and charybdotoxin, we suggested that Lys 19 of PVIIA is the residue 
responsible for physically occluding the pore of the potassium channel. 
 
Common Structural Frameworks. 
 
From the studies described above it has become clear that conotoxins with the six cysteine / four-loop framework 
are the most abundant group of peptides isolated from Conus venoms so far. This structural class encompasses at 
least five known pharmacological classes: w-conotoxin calcium channel blockers, d-conotoxins which inhibit the 
inactivation of sodium channels, k- conotoxin PVIIA which blocks potassium channels, the sodium channel blocker 
conotoxin GS, and two peptides recently found in C. marmoreus that affect both sodium and calcium currents 
[Myers et al., 1993; Cruz, 1996; Terlau et al., 1996]. The solution structures of several of these classes have now 
been determined, including the w-conotoxins, k-conotoxin, and GS, and all contain a triple-stranded antiparallel b-
sheet with +2x, -1 topology and cystine knot motif common to that observed in a number of toxic and inhibitory 
peptides [Pallaghy et al., 1994; Narasimhan et al., 1994]. 
Thus, there are now many examples where one structural framework is associated with different 
pharmacological activities. Interestingly, the converse also occurs; that is, the same pharmacological activity may be 
associated with completely different structural frameworks, as demonstrated, for example, with the studies described 
above on the m-conotoxins and conotoxin GS. 
 
Conclusions 
 
Conotoxins provide a vast library of peptides with unique abilities to discriminate among types and subtypes of ion 
channels in a manner that is unmatched by the typical small molecule drugs which dominate the pharmaceutical 
industry. In addition, cone venom peptides are small and inherently stable, making them ideal leads for peptide 
therapeutics, especially ion channel therapeutics. The high structural resolution now obtained with modern NMR 
spectroscopy and X-ray crystallography provides emerging opportunities to use conotoxins as templates for the 
design of smaller peptidomimetics that incorporate the selectivity and potency of conotoxins. Because of its 
selectivity and potency, w-conotoxin MVIIA (Ziconotide) is being developed as a drug for the treatment of chronic 
pain. Conotoxins continue to be discovered that define new pharmacological targets. With improvement in methods 
of delivering peptides, it is anticipated that conopeptides can be modified for effective oral delivery. 
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